

ULTRAPETROL BAHAMAS LTD  
Form 6-K  
March 08, 2012

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2012.**

Commission File Number: **001-33068**

**Ultrapetrol (Bahamas) Limited**

(Translation of registrant's name into English)

**Ocean Centre, Montagu Foreshore  
East Bay St.  
Nassau, Bahamas  
P.O. Box SS-19084**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F [  ] Form 40-F [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes [  ] No [  ]

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_.

---

On March 8, 2012 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated March 8, 2012

---

Edgar Filing: ULTRAPETROL BAHAMAS LTD - Form 6-K

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Ultrapetrol (Bahamas) Limited**

(Registrant)

Date: March 8, 2012

**/s/ LEONARD J. HOSKINSON**

Leonard J. Hoskinson  
*Chief Financial Officer*

padding:0in 0in 0in 0in;width:2.0%;">

**06-1047163**

(State or other jurisdiction of  
incorporation or organization)

(Commission file number)

(IRS employer identification  
number)

**500 Kendall Street, Cambridge, Massachusetts 02142**

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code:

**(617) 252-7500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On October 22, 2007, Genzyme Corporation announced that the stockholders of Bioenvision, Inc. voted to approve the merger of Wichita Bio Corporation, a wholly-owned subsidiary of Genzyme, with and into Bioenvision. The merger was effective as of 12:01AM EST on October 23, 2007. A copy of the press release is included as Exhibit 99.1 hereto.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GENZYME CORPORATION**

Dated: October 22, 2007

By: /s/ Peter Wirth  
Peter Wirth  
Executive Vice President and  
Chief Legal Officer

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits

99.1 Press Release of Genzyme Corporation dated October 22, 2007.